{
    "nctId": "NCT03149081",
    "briefTitle": "A \"Window Trial\" on Boswellia for Breast Cancer Primary Tumors",
    "officialTitle": "A \"Window Trial\" on Boswellia, an Extract From Frankincense, for Breast Primary Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Change in tumor proliferation rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed ductal carcinoma in situ (DCIS) or invasive breast cancer (stages I, II, or III) with primary tumor(s) \u2265 1.0 cm on mammogram, ultrasound, MRI, or physical exam\n* 18 years of age or older\n* Subject must understand risks and benefits of the protocol and be able to give informed consent\n* Females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test result before and throughout the study\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematologic and end organ function\n* Ability and capacity to comply with the study and follow-up procedure\n* Subjects must be scheduled for surgery at MUSC no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1.\n* At least 6 sections of unstained slides should be obtained. If sufficient slides or tissue is unavailable, the patient will be excluded from the trial.\n\nExclusion Criteria:\n\n* Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy\n* Subjects with end-stage kidney disease and/or grade II liver dysfunction\n* Subject has active or history of deep vein thrombosis (DVT)\n* Subject has a history of coagulopathies or hematological disorders\n* Subjects who are pregnant or are lactating.\n* Subjects already taking drugs known to be 5-lipoxygenase inhibitors (Refer to section 5)\n* Subjects taking drugs that interact with OATP1B3 (an anion transporter), MRP2 (a multidrug resistant protein), and/or P-Glycoprotein (P-Gp) (Refer to section 5.)\n* Subjects taking anti-coagulants or platelet inhibitors (Refer to section 5)\n* Subjects with bowel obstruction\n* Subjects undergoing emergency surgery.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}